Imagine a future where high-risk heart procedures become safer and more accessible. That's the promise of a groundbreaking device called NyokAssist, a small-bore percutaneous ventricular assist device (pVAD) from China, which is shaking up the world of cardiology. But here's where it gets controversial: could this device truly replace the long-standing intra-aortic balloon pump (IABP) in high-risk PCI procedures? The SAVE-PCI trial, presented at TCT 2025, suggests it might just be possible.
In a head-to-head comparison, NyokAssist demonstrated comparable safety and efficacy to IABP in stabilizing patients during elective, high-risk PCI. The 30-day results revealed similar rates of major adverse cardiac and cerebrovascular events (MACCE) in both groups, with minimal adverse events reported among Chinese PCI patients. This is no small feat, especially considering the device's innovative external motor design, which not only reduces costs but also eliminates heat-related blood damage—a common concern with traditional pVADs.
And this is the part most people miss: NyokAssist's small-bore 9-Fr insertion profile significantly reduces the risk of vascular complications, a persistent issue with larger-bore pVADs. Investigator Rui Wang, MD, PhD, highlighted this advantage, emphasizing the device's smooth insertion, navigation, and withdrawal, coupled with a slower rotational speed. This design could be a game-changer for patients who are at higher risk of bleeding complications.
However, the study isn’t without its limitations. Holger Thiele, MD, pointed out that while the trial boasts a complete lack of vascular complications, it is relatively small and includes patients who aren’t as high-risk as those in previous studies like BCIS-1 and PROTECT II. Is this a step forward or a missed opportunity? The debate is far from over, and upcoming trials like PROTECT IV and CHIP-BCIS3 will play a crucial role in determining the best hemodynamic support for high-risk PCI.
The SAVE-PCI trial enrolled 236 hemodynamically stable patients across 11 centers in China, randomizing them to receive either NyokAssist or IABP. The results were striking: at 30 days, MACCE rates were nearly identical (4.4% vs. 2.6%), with no significant differences in mortality, repeat revascularization, stroke, or myocardial infarction. Major adverse events were rare, with only a few cases of acute renal failure and ventricular arrhythmia reported.
But here’s the million-dollar question: Can NyokAssist save lives where IABP cannot? Sanjit Jolly, MD, raises a critical point: while VAD devices like NyokAssist offer more robust support, their value lies in identifying the right patients who truly need them. If it’s a matter of life and death, the cost is justifiable. But if the primary benefit is a smaller tube and reduced vascular complications, patients and payers might hesitate to foot the bill. As more devices enter the market, competition could drive down costs, making these innovations more accessible.
As we await the results of PROTECT IV, one thing is clear: the landscape of hemodynamic support in high-risk PCI is evolving rapidly. What do you think? Is NyokAssist the future of PCI support, or is it too early to crown a winner? Share your thoughts in the comments below and join the conversation!
